Nanalysis Scientific (TSXV:NSCI) - Aandelenkoers, Nieuws & Analyse

NSCI Overzicht aandelen

Nanalysis Scientific Corp. ontwikkelt, produceert en verkoopt magnetische resonantie technologische producten in Canada, de Verenigde Staten, Canada, Europa, Azië en internationaal.

Over het bedrijf

NSCI fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 50.2% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( CA$41M )

Nanalysis Scientific Corp. Concurrenten

NuGen Medical Devices

TSXV:NGMD

CA$20.7m

Perimeter Medical Imaging AI

TSXV:PINK

CA$43.0m

Aurora Spine

TSXV:ASG

CA$30.2m

Conavi Medical

TSXV:CNVI

CA$51.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Nanalysis Scientific
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.36
52 Week Hoogtepunt	CA$0.60
52 Week Laag	CA$0.33
Bèta	0.72
11 maand verandering	-8.86%
3 maanden verandering	-8.86%
1 Jaar Verandering	-13.25%
33 jaar verandering	-75.17%
5 jaar verandering	-33.33%
Verandering sinds IPO	-34.55%

Recent nieuws en updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Oct 28

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 19

Recent updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Oct 28

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 19

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 12

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Mar 24

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Feb 08

Rendement voor aandeelhouders

	NSCI	CA Medical Equipment	CA Markt
7D	-6.5%	-2.7%	-1.1%
1Y	-13.3%	-6.5%	20.8%

Rendement versus industrie: NSCI presteerde slechter dan de Canadian Medical Equipment -sector, die het afgelopen jaar een rendement van -6.5 % opleverde.

Rendement versus markt: NSCI presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 20.8 % opleverde.

Prijsvolatiliteit

Is NSCI's price volatile compared to industry and market?
NSCI volatility
NSCI Average Weekly Movement	8.4%
Medical Equipment Industry Average Movement	13.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: NSCI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van NSCI is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	249	Sean Krakiwsky	www.nanalysis.com

Nanalysis Scientific Corp. ontwikkelt, produceert en verkoopt magnetische resonantie technologische producten in Canada, de Verenigde Staten, Canada, Europa, Azië en internationaal. Het bedrijf opereert via het segment wetenschappelijke apparatuur en beveiligingsdiensten. Het biedt nucleaire magnetische resonantie (NMR) spectrometers; magnetische resonantie test-, en meet- en diagnosesystemen; 60 MHz en 100 MHz NMR platform; en Cameleon 4 console, een compact alternatief om MRI voor het onderwijs te vergemakkelijken.

Nanalysis Scientific Corp. Samenvatting

Hoe verhouden de winst en inkomsten van Nanalysis Scientific zich tot de beurswaarde?
NSCI fundamentele statistieken
Marktkapitalisatie	CA$40.72m
Inkomsten(TTM)	-CA$12.93m
Inkomsten(TTM)	CA$39.47m

1.0x

P/S-verhouding

-3.1x

Koers/Winstverhouding

Is NSCI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NSCI resultatenrekening (TTM)
Inkomsten	CA$39.47m
Kosten van inkomsten	CA$30.63m
Brutowinst	CA$8.84m
Overige uitgaven	CA$21.77m
Inkomsten	-CA$12.93m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.11
Brutomarge	22.40%
Nettowinstmarge	-32.75%
Schuld/Eigen Vermogen Verhouding	61.0%

Hoe presteerde NSCI op de lange termijn?

Bekijk historische prestaties en vergelijking

NSCI Overzicht aandelen

Beloningen

Risicoanalyse

Nanalysis Scientific Corp. Concurrenten

TSXV:NGMD

CA$20.7m

TSXV:PINK

CA$43.0m

TSXV:ASG

CA$30.2m

TSXV:CNVI

CA$51.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Second quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 2Q 2023)

Nanalysis Scientific Corp. to Report Q2, 2024 Results on Aug 28, 2024

High number of new and inexperienced directors

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.042 loss in 1Q 2023)

Recent updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Second quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 2Q 2023)

Nanalysis Scientific Corp. to Report Q2, 2024 Results on Aug 28, 2024

High number of new and inexperienced directors

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.042 loss in 1Q 2023)

Nanalysis Scientific Corp. to Report Q1, 2024 Results on May 29, 2024

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.098 loss in FY 2022)

Nanalysis Scientific Corp., Annual General Meeting, Jun 26, 2024

Nanalysis Scientific Corp. to Report Q4, 2023 Results on Apr 25, 2024

Nanalysis Scientific Corp. Announces Resignation of Kham Lin as A Director

Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 5 million.

Nanalysis Scientific Corp. announced that it expects to receive CAD 1 million in funding

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Nanalysis Scientific Corp. Provides Earnings Guidance for the Fourth Quarter 2023

We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt

Third quarter 2023 earnings released: CA$0.06 loss per share (vs CA$0.026 loss in 3Q 2022)

Nanalysis Scientific Corp. to Report Q3, 2023 Results on Nov 29, 2023

Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?

Second quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.024 loss in 2Q 2022)

Nanalysis Scientific Corp. to Report Q2, 2023 Results on Aug 24, 2023

Nanalysis Scientific Corp. to Report Q1, 2023 Results on May 25, 2023

Nanalysis Scientific Corp. announced that it has received CAD 4.1287 million in funding

Full year 2022 earnings released: CA$0.10 loss per share (vs CA$0.025 loss in FY 2021)

Nanalysis Scientific Corp.'s (CVE:NSCI) Price Is Right But Growth Is Lacking

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Third quarter 2022 earnings released

Nanalysis Scientific Corp. to Report Q3, 2022 Results on Nov 29, 2022

Price target decreased to CA$2.75

High number of new and inexperienced directors

Nanalysis Scientific Corp. Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Price target decreased to CA$2.75

Nanalysis Scientific Corp. to Report Q2, 2022 Results on Aug 25, 2022

Nanalysis Scientific Corp. Announces Executive Changes

Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?

Nanalysis Scientific Corp. Announces Appointment of Kham Lin as New Director

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.007 loss in 1Q 2021)

Nanalysis Scientific Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.056 loss in FY 2020)

High number of new and inexperienced directors

Nanalysis Scientific Corp. to Report Fiscal Year 2021 Results on Apr 28, 2022

Nanalysis Scientific Corp. has completed a Follow-on Equity Offering in the amount of CAD 10.725 million.

Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?

Nanalysis Scientific Corp. (TSXV:NSCI) completed the acquisition of K'(Prime) Technologies Inc.

Nanalysis Scientific Corp. announced that it expects to receive CAD 0.2025 million in funding

High number of new and inexperienced directors

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.017 loss in 3Q 2020)

Second quarter 2021 earnings released

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 8.00004 million.

Nanalysis Scientific Corp. announced that it has received CAD 1.797638 million in funding

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.014 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.056 loss per share (vs CA$0.03 loss in FY 2019)

Is Nanalysis Scientific (CVE:NSCI) Using Debt Sensibly?

Nanalysis Scientific Corp. Signs Strategic OEM Partnership for Magnetic Resonance Electronics Sales

New 90-day high: CA$0.50

Nanalysis Scientific (CVE:NSCI) Has Debt But No Earnings; Should You Worry?